The Regenstrief Institute Inc., an Indianapolis, Ind.-based informatics and health care research organization, has become a member of ConvergeHEALTH, Deloitte’s real-world evidence and analytics consortium.
Regenstrief joins Intermountain Healthcare and Moffitt Cancer Center/M2Gen as part of a rapid-learning network established by ConvergeHEALTH to support the health industry’s shift toward a value-based system featuring personalized medicines. Acording to thew announcement, the collaboration will potentially help life-sciences manufacturers and academic institutions more effectively identify evidence opportunities by reducing the time required to conduct retrospective analyses and prospective research related to comparative effectiveness and drug safety. Other studies can be streamlined by better identifying underserved populations, predicting effectiveness and pinpointing the right patients for deeper studies.
In addition to the benefits for life-sciences companies, the Regenstrief collaboration will help health care providers determine better treatments based on clinical data and associated patient outcomes in targeted sub-populations. This is becoming increasingly important as reimbursement models shift toward value and population health.
“Our center for biomedical informatics has one of the largest and most diverse sets of longitudinal patient data today,” said William M. Tierney, M.D. president and chief executive officer of Regenstrief Institute and associate dean for clinical effectiveness research at the Indiana University School of Medicine, in a prepared statement. He added that ConvergeHEALTH’s OutcomesMiner platform, combined with Regenstrief’s our longitudinal data and research capabilities, will help life-sciences manufacturers and other collaborators accelerate studies and ultimately create more efficient therapies.
Leveraging electronic medical records and other health data, OutcomesMiner helps users explore real-world outcomes for sub-populations of interest. The ConvergeHEALTH rapid-learning network also enables collaborators to conduct studies to develop further evidence to support comparative effectiveness research, product planning, health economic and outcomes research and observational insights that support safety analytics and commercial decision-making.